Alternative Pain Therapy for Breast, Prostate and Lung Cancer

MIAMI–BUSINESS WIRE — Bio-Nucleonics’ lead product Strontium Chloride Sr-89 Injection USP (Strontium-89), which is the generic version of Metastron®, is an option to consider for metastatic cancer bone pain therapy, typically caused by advanced stage breast, prostate or lung cancer.

Generic Strontium Chloride Sr-89 Injection USP (Strontium-89) is a radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. In the body, Strontium acts similar to calcium and is preferentially taken up in osteoblastic tissue while the unabsorbed isotope is excreted in the urine the first 2 to 3 days following injection, clearing rapidly from the blood and selectively localizing in bone mineral. Uptake of strontium by bone occurs preferentially in sites of active osteogenesis; thus primary bone tumors and areas of metastatic involvement (blastic lesions) can accumulate significantly greater concentrations of strontium than surrounding normal bone.

Generic Strontium Chloride Sr-89 Injection USP can be replaced or used in combination with opiate based drugs like Oxycotin®, Morphine, Percocet® as well as cancer therapeutic drugs. Clinical studies have demonstrated that the combination of alternating weekly chemohormonal therapies with Sr-89 demonstrated a prolonged progression-free and overall survival with acceptable toxicity.

“For more than a decade, Bio-Nucleonics has been providing us with Generic Strontium Chloride Sr-89 for the palliation of painful bone metastases. Strontium has been a God-send and has proved invaluable in providing patients with dramatic pain relief from the debilitating chronic pain of metastatic bone cancer without the side effects caused by opioids.” stated Dr. Ernie Meth, of Temecula Valley Nuclear Medicine.

ABOUT BIO-NUCLEONICS:

Bio-Nucleonics, Inc., is a privately-held, life sciences company, specializing in the development, manufacture and marketing of radiopharmaceuticals, medical devices and imaging agents for the detection and treatment of oncological, cardiovascular, and neurological diseases. The Company has a product development pipeline including several new drug applications with products in various stages of development. The Company’s business strategy is to capitalize on its proven expertise targeted to improving patient care and quality-of-life.

On May 19th, 2014, posted in: 2011, Bio-Nucleonics News by